|
Ä¿¸®¾îÄɾî |
´Ù±¹ÀûÁ¦¾àȸ»ç CSO (Clinical Safety Officer)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
09.27 |
|
|
(ÁÖ)KoreaHR |
Major Á¦¾à»ç - (¾à»ç) PV Manager °æ·Â 1³âÀÌ»óÀÚ ¸ðÁý
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
11.26 |
|
|
Àª¾ØºñÀü |
[6°³¿ù/¿ë»ê] ¿Ü±¹°èÁ¦¾à¼ PVÆÀ »ç¹«Admin ´ëÇлý ÀÎÅÏ Ã¤
¼¿ï ¿ë»ê±¸, ¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.14 |
|
|
¿ÍÀÌ¿¥Ä¿¸®¾î |
[ÄÚ½º´Ú»óÀå À¯¸Á ¹ÙÀÌ¿À ±â¾÷] ¾à¹°°¨½Ã(PV) ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.25 |
|
|
¸®Å©·çÆ® |
±Û·Î¹ú Á¦¾à.¹ÙÀÌ¿À»ç PV(3³âÀÌ»ó)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
10.01 |
|
|
HRKorea |
Pharmacovigilance Specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
3³â¡è |
ä¿ë½Ã |
05.18 |
|
|
À̳ë¼Ä¡ |
±Û·Î¹úÁ¦¾à¹ÙÀÌ¿À PV [Pharmacovigilance]
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
06.15 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
»óÀå ¹ÙÀÌ¿ÀÁ¦¾à»ç ÀÓ»ó PV °æ·Â ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.27 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ(ÁÖ) |
À¯¸í Á¦¾à ȸ»ç ÀÓ»ó°³¹ßÆÀ ºÎ¹® / Çã°¡ÀÓ»ó (´ë¸®,°úÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) ÀçÇÐ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.19 |
|
|
(ÁÖ)À¯ºñ¼Ò½Ã¾î½º |
±¹³» Áß°ß Á¦¾à»ç, pvÆÀ¿ø, ÆÀÀå ä¿ë
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
4³â¡è |
ä¿ë½Ã |
01.22 |
|
|
¿¢½º´ÙÀÓ(ÁÖ) |
Post-Marketing Surveillance (´ë¸®~°úÀå) - ±¹³» À¯¸í Á¦¾à
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
À̳ë¼Ä¡ |
±Û·Î¹úÁ¦¾à»çPV, ±Û·Î¹úCRO RA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
08.30 |
|
|
ÆÄÀε崺·ÎµåÄÁ¼³Æà |
Patient Safety Lead (Â÷ºÎÀå±Þ) / ¿Ü±¹°è Á¦¾à»ç
¼¿ï ÀüÁö¿ª, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
6³â¡è |
ä¿ë½Ã |
05.03 |
|
|
HRKorea |
ÀǾàÇ° ¾à¹°°¨½Ã(PV) ¾÷¹«-±¹³» ¹× ÇØ¿Ü °³º°ÀÌ»ó»ç·Ê(ICSR)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
12.24 |
|
|
K1partners |
[±¹³»Áß°ßÁ¦¾à»ç] °³¹ßºÎ ÆÀ¿ø ¹× ÆÀÀå ä¿ë(½ÅÀÔ¾à»ç ¹× °æ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.17 |
|